Document 0111
 DOCN  M95A0111
 TI    Foscarnet decreases human immunodeficiency virus RNA.
 DT    9510
 AU    Kaiser L; Perrin L; Hirschel B; Furrer H; Von Overbeck J; Olmari M;
       Yerly S; Division of Infectious Diseases, University Hospital, Geneva,;
       Switzerland.
 SO    J Infect Dis. 1995 Jul;172(1):225-7. Unique Identifier : AIDSLINE
       MED/95318528
 AB    Foscarnet inhibits human immunodeficiency virus (HIV) replication in
       vitro and decreases p24 antigenemia in patients with cytomegalovirus
       (CMV) retinitis. To evaluate the effect of foscarnet on HIV replication,
       HIV RNA was quantitated in 17 patients before and during foscarnet
       therapy. Fifteen patients had CMV retinitis, 1 had CMV encephalitis, and
       1 had intractable zoster. A decrease in HIV RNA was observed in 16 of 17
       patients. Before the introduction of foscarnet, mean HIV RNA was 5.82
       +/- 0.24 log RNA/mL and, after a median of 13 days of therapy, mean HIV
       RNA was 5.30 +/- 0.27 log RNA/mL (P < .001). Among patients with
       detectable p24 antigen at baseline, a significant decrease was observed
       (P = .017). This decrease in HIV RNA demonstrates that foscarnet is a
       potent antiretroviral drug.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS/IMMUNOLOGY/  *VIROLOGY
       AIDS-Related Opportunistic Infections/*DRUG THERAPY/IMMUNOLOGY/
       MORTALITY  Cytomegalovirus Infections/*DRUG THERAPY/ETIOLOGY/MORTALITY
       CD4 Lymphocyte Count  Flow Cytometry  Foscarnet/*THERAPEUTIC USE  Human
       HIV/DRUG EFFECTS/*GENETICS  HIV Core Protein p24/ANALYSIS/BIOSYNTHESIS
       Prospective Studies  Retrospective Studies  RNA, Viral/ANTAGONISTS &
       INHIB/*BIOSYNTHESIS  Survival Rate  Time Factors  CLINICAL TRIAL
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).